Oral Raav Delivery
Oral Raav Delivery - Related Videos
05:34
Oral Delivery of Transformed Yeast Cells into the Mouse Intestinal Immune System
0 Views •
2025
This video showcases the oral administration of transformed yeast cells into a mouse model. The transformed yeast cells are orally administered using a gavage technique, reaching the mouse's stomach. Later, the cells migrate to the small intestine, where microfold cells engulf them and facilitate their transfer to Peyer's patches and gain access to the intestinal immune system.
01:23
Oral Drug Delivery Systems: Introduction
0 Views •
2026
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
06:29
A Simple and Precise Feed-Based Approach to Oral Drug Delivery in Fish
0 Views •
2026
This study presents a gelatin-based feeding method that enables precise, non-invasive, body mass–based oral drug delivery in adult zebrafish. The protocol demonstrates reliable feed acceptance and, as a proof-of-principle, successful delivery of MK-801, which resulted in the expected behavioral effects.
01:26
Oral Drug Delivery Systems: Continuous-Release Systems
0 Views •
2026
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
04:28
Utilizing an Orally Dissolving Strip for Pharmacological and Toxicological Studies: A Simple and Humane Alternative to Oral Gavage for Animals
0 Views •
Cited by 4 •
2016
The following protocol describes a novel method for chronic oral drug administration using an orally dissolving strip (ODS) in lieu of the more commonly used oral gavage method. We demonstrate that preclinical, oral drug delivery using the ODS method represents a safe, convenient, and humane alternative to oral gavage.
FAQs
Digestive conditions can threaten vector stability before the particles reach intestinal tissues. Formulation and protective strategies therefore help preserve the vector during gastrointestinal transit, increasing the possibility that intact particles will contact and enter target cells. This design consideration is central to improving uptake and addressing one of the main barriers to effective oral gene transfer.
Capsid selection can affect whether the vector reaches suitable intestinal tissues and enters the intended cell types. Different capsid choices are therefore evaluated for tissue specificity and transduction efficiency, meaning the ability to transfer the therapeutic gene into cells. In oral applications, selection must be considered together with gastrointestinal stability rather than treated as an isolated vector property.
After the capsid releases the therapeutic gene inside a target cell, episomal expression can support production of the encoded genetic product. This mechanism is relevant because the desired outcome may be protein production within intestinal tissues or, potentially, a broader systemic effect. The level and location of expression depend on successful delivery, cellular entry, and vector design.
The principal distinction is the administration route: oral delivery avoids injection and uses the gastrointestinal tract as the entry pathway. That noninvasive feature may improve its practical appeal, but it also introduces requirements that injection-based approaches do not share, including survival through digestion, intestinal tissue access, and efficient transduction after oral administration.
A typical workflow begins by selecting an appropriate capsid and preparing a formulation that helps protect the vector during gastrointestinal passage. After oral administration, the particles must remain sufficiently stable, reach intestinal tissues, enter target cells, and release the therapeutic gene. These sequential requirements explain why formulation, capsid choice, and transduction efficiency are studied together.
The key design elements are the recombinant adeno-associated virus vector, its capsid, and a formulation that supports protection during gastrointestinal transit. Researchers also consider how these components affect intestinal tissue access and cellular entry. Adjusting these features aims to improve vector stability, uptake, tissue specificity, and the resulting expression of the therapeutic gene.
This approach may be investigated for intestinal disorders where gene transfer directly to gastrointestinal tissues could be useful. It may also support localized protein production, while some designs aim for broader systemic gene delivery. Its relevance in genetics comes from linking vector design and administration route to where a therapeutic gene is expressed and how effectively it reaches target cells.